CG Oncology, Inc. Common stock
NASDAQ: CGON0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Arthur Kuan
- Employees
- 113
- Headquarters
- Irvine, United States
- IPO year
- 2024
- Market cap
- $5.4B
- Website
- https://cgoncology.com
Loading CGON…
Loading profile data…Frequently asked questions about CGON
What does CG Oncology, Inc. Common stock (CGON) do?
CG Oncology Inc. is a biotechnology company in the clinical development stage, committed to advancing and bringing to market an innovative, bladder-sparing core treatment for individuals diagnosed with bladder cancer. Their principal drug candidate, cretostimogene, is presently undergoing clinical evaluation. Its initial focus is on providing a...
Where does CGON trade?
CG Oncology, Inc. Common stock (CGON) trades on the NASDAQ Global Select.
What sector is CGON in?
CG Oncology, Inc. Common stock (CGON) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CG Oncology, Inc. Common stock?
Arthur Kuan is the chief executive officer of CG Oncology, Inc. Common stock (CGON).
Where is CG Oncology, Inc. Common stock headquartered?
CG Oncology, Inc. Common stock is headquartered in United States.
Does CGON pay a dividend?
CG Oncology, Inc. Common stock (CGON) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CGON go public?
CG Oncology, Inc. Common stock (CGON) completed its initial public offering in 2024.